RYTM — Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Q3 2025 global revenue reached $51.3 million, a 6% increase from Q2 2025 ($48.5 million) and a 54% increase year-over-year from Q3 2024.
• U.S. Revenue: $38.2 million (74% of total revenue), with a high single-digit percentage increase in the number of reimbursed patients.
• International Revenue: $13.1 million (26% of total revenue), impacted by a one-time charge of $3.2 million related to reimbursement agreements in France.
• Cash Position: Ended the quarter with $416.1 million in cash, providing at least 24 months of operational runway.
• Net Loss: GAAP EPS was a loss of $0.82 per share.

2. Strategic Updates and Business Highlights

• Product Launch: Preparing for the launch of IMCIVREE for acquired hypothalamic obesity (HO) pending FDA approval, with a PDUFA date set for December 20, 2025.
• Sales Growth: Continued growth in IMCIVREE sales for Bardet-Biedl syndrome (BBS), with a 10% increase in the number of patients on reimbursed therapy.
• Regulatory Progress: Both the FDA and EMA accepted regulatory filings for HO, with promising dialogues indicating potential approvals in the near future.
• International Expansion: IMCIVREE is now available in over 25 countries, with ongoing efforts to secure reimbursement in France and Italy for HO.

3. Forward Guidance and Outlook

• Upcoming Milestones: Anticipate preliminary results from the exploratory Phase II trial in Prader-Willi syndrome (PWS) by the end of 2025, and further data releases in early 2026.
• Operating Expense Guidance: Tightened full-year operating expense guidance to $295 million to $315 million, with a focus on supporting the upcoming HO launch.

4. Challenges and Points of Concern

• International Revenue Variability: International revenue decreased by $3.4 million due to variability in ordering patterns and the impact of the one-time charge in France.
• Clinical Trial Complexity: The PWS trial is challenging due to the complexity of the disease, with a neutral prediction of a 50-50 chance of success in demonstrating efficacy.
• Market Education: The need for extensive education among physicians and payers regarding the differentiation of HO from general obesity may slow the launch ramp-up.

5. Notable Q&A Insights

• HO Launch Strategy: Discussions with payers are ongoing, and the company is optimistic about securing reimbursement even before formal policies are established post-approval.
• PWS Trial Design: The Phase II trial for PWS may not yield a definitive go/no-go decision immediately, as the data set will be small and require careful interpretation.
• Combination Therapy Potential: There is interest in understanding how IMCIVREE may work in conjunction with existing therapies for PWS, although the mechanisms are different.
• Launch Curve Expectations: The launch curve for HO may differ from BBS due to the distribution of patients among community endocrinologists rather than specialized centers.

Overall, Rhythm Pharmaceuticals is positioned for significant growth with the upcoming launch of IMCIVREE for HO, while navigating challenges related to international revenue and clinical trial complexities.